Unboosted versus boosted atazanavir for reducing morbidity and mortality in people with HIV/AIDS
Editorial Group: Cochrane HIV/AIDS Group
Published Online: 11 JUL 2012
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Cohen K, Kredo T, de Waal R. Unboosted versus boosted atazanavir for reducing morbidity and mortality in people with HIV/AIDS (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD005418. DOI: 10.1002/14651858.CD005418.pub2.
- Publication Status: Amended to reflect a change in scope (see 'What's new')
- Published Online: 11 JUL 2012
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine whether unboosted atazanavir-containing regimens are more effective and safe than boosted atazanavir-containing regimens in reducing morbidity and mortality in people living with HIV/AIDS.